Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients.
1H-NMR
hepatitis C virus (HCV)
ribavirin (RBV)
severe liver fibrosis
urinary metabolites
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Sep 2022
02 Sep 2022
Historique:
received:
16
07
2022
revised:
26
08
2022
accepted:
31
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
The most commonly used antiviral treatment against hepatitis C virus is a combination of direct-acting antivirals (DAAs) and ribavirin (RBV), which leads to a shortened duration of therapy and a sustained virologic response until 98%. Nonetheless, several dose-related side effects of RBV could limit its applications. This study aims to measure the urinary concentration of RBV and its main metabolites in order to evaluate the drug metabolism ability of HCV patients and to evaluate the adverse effects, such as anemia, with respect to RBV metabolite levels. RBV and its proactive and inactive metabolites were identified and quantified in the urine of 17 HCV males with severe liver fibrosis using proton nuclear magnetic resonance (
Identifiants
pubmed: 36077436
pii: ijms231710043
doi: 10.3390/ijms231710043
pmc: PMC9456413
pii:
doi:
Substances chimiques
Antiviral Agents
0
Recombinant Proteins
0
Ribavirin
49717AWG6K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Antimicrob Agents Chemother. 1999 Nov;43(11):2716-9
pubmed: 10543752
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Expert Opin Pharmacother. 2016 Jun;17(9):1215-23
pubmed: 27149603
Liver Int. 2021 Aug;41(8):1802-1814
pubmed: 33497016
J Viral Hepat. 2019 Oct;26(10):1210-1217
pubmed: 31197910
Nature. 2010 Mar 18;464(7287):405-8
pubmed: 20173735
New Microbiol. 2021 Jan;44(1):12-18
pubmed: 33453702
Hepatology. 2000 Apr;31(4):997-1004
pubmed: 10733558
J Chromatogr Sci. 2019 Aug 1;57(7):636-643
pubmed: 31063182
Circ Res. 1990 Mar;66(3):754-62
pubmed: 1689616
Hepatology. 2017 Oct;66(4):1090-1101
pubmed: 28504842
Prog Nucl Magn Reson Spectrosc. 2017 Nov;102-103:1-14
pubmed: 29157489
Ann N Y Acad Sci. 1977 Mar 4;284:211-29
pubmed: 280136
Gastroenterology. 2015 Sep;149(3):649-59
pubmed: 25985734
Gastroenterology. 2017 Jan;152(1):164-175.e4
pubmed: 27720838
Electrophoresis. 2004 Jun;25(10-11):1615-22
pubmed: 15188249
Arch Med Res. 2021 Oct;52(7):692-702
pubmed: 33966916
Biomed Pharmacother. 2021 Nov;143:112217
pubmed: 34560544
Clin Pharmacokinet. 2014 May;53(5):409-27
pubmed: 24723109
J Nutr. 2013 Oct;143(10):1549-57
pubmed: 23946343
J Clin Transl Hepatol. 2018 Dec 28;6(4):431-437
pubmed: 30637222
Antimicrob Agents Chemother. 1989 Mar;33(3):311-5
pubmed: 2729926
Cell Mol Life Sci. 2006 Apr;63(7-8):832-42
pubmed: 16501888
Ann Hepatol. 2019 May - Jun;18(3):434-438
pubmed: 31023614
Hepatology. 2011 Oct;54(4):1433-44
pubmed: 21898493
Gastroenterology. 2010 Oct;139(4):1181-9
pubmed: 20547162
Biol Chem. 2006 Mar;387(3):319-21
pubmed: 16542154
Antimicrob Agents Chemother. 2003 Apr;47(4):1395-8
pubmed: 12654676
Nat Med. 2000 Dec;6(12):1375-9
pubmed: 11100123
Antimicrob Agents Chemother. 2013 Jul;57(7):3147-58
pubmed: 23629707
Br J Clin Pharmacol. 2003 Apr;55(4):360-7
pubmed: 12680884
Dig Liver Dis. 2011 May;43(5):411-5
pubmed: 21310673
Sci Rep. 2016 Dec 19;6:39454
pubmed: 27991578
Viruses. 2012 Aug;4(8):1264-78
pubmed: 23012624
Pharmacogenomics. 2016 Jun;17(8):925-41
pubmed: 27248282
Biochem Pharmacol. 2014 Jun 15;89(4):441-52
pubmed: 24735613
Antivir Chem Chemother. 2012 Sep 25;23(1):1-12
pubmed: 22592135
Clin Chim Acta. 2020 Mar;502:269-279
pubmed: 31778675
J Gastroenterol. 2004;39(2):155-61
pubmed: 15069622
Magn Reson Chem. 2013 Sep;51(9):549-56
pubmed: 23828598